DRTS Alpha Tau Medical Ltd.
USHealthcareAs of 2026-07-10 16:00
Why DRTS matters now
Alpha Tau Medical Ltd. (DRTS) is a US stock in Healthcare. The latest InvestLog snapshot shows $12.71 with -2.08% on the session and $1.15B in market capitalization; recent performance reads 1-month -8.43% and YTD +97.58%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-22.9M, and EPS of $-0.26. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.7%.
The latest indexable market news headline is "New Strong Sell Stocks for July 7th" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $15.00; recent insider activity includes Levy Raphi filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
12.65
P/S
0.00
EV/EBITDA
-19.79
DCF Value
$-0.02
FCF Yield
-3.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-73.2%
ROA
-52.3%
ROIC
-46.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-22.9M | $-0.26 |
| Q4 2025 | $0.00 | $-12.1M | $-0.14 |
| FY 2025 | $0.00 | $-42.6M | $-0.53 |
| Q3 2025 | $0.00 | $-11.7M | $-0.14 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$13.33
Target (Median)
$15.00
Target Range
$8.00 - $17.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IL
Exchange
—
Beta
1.20
Alpha Tau Medical Ltd. is a clinical-stage biotechnology company dedicated to the advancement and eventual commercialization of innovative cancer treatments. Their primary focus is on "Alpha DaRT" (Diffusing Alpha-Emitters Radiation Therapy), a novel approach designed to combat solid tumors. This therapeutic radiation technique is currently undergoing clinical evaluation for various solid malignancies, including skin, oral, pancreatic, and breast cancers, with development efforts primarily concentrated in Israel and the United States. Furthermore, Alpha DaRT is being explored in preclinical investigations for additional challenging cancers such as hepatic cell carcinoma, glioblastoma multiforme (a type of brain tumor), and lung cancer, among others. Established in 2015, the company maintains its headquarters in Jerusalem, Israel.